Vitiligo
Drug research and approvals for vitiligo: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.
As of Nov 21, 2026, 43 studies of vitiligo are recruiting on ClinicalTrials.gov, Health Canada has authorized 25 drug trials for it since 2013, and the EU has 1 authorised medicine for it.
- Recruiting worldwide: 43
- Trials authorized in Canada: 25
- FDA orphan approvals: 0
- EU medicines: 1
- Gut Microbiome Diversity in Adults With Inflammatory and Immune-Mediated Skin DiseasesNCT07944196 · Not reported · Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico · starts Apr 11, 2026
- Evaluation of Crisaborole 2% Versus Tacrolimus 0.1% Each Combined With Excimer Light in the Treatment of Stable…NCT07904910 · Phase 3 · Cairo University · starts May 15, 2026
- A Study of EB06 Versus Placebo in Adults With Moderate to Severe Non-segmental VitiligoNCT07889492 · Phase 2 · Edesa Biotech Inc. · starts Aug 5, 2026
- Assessment of Vitiligo Lesions Using Polarized Dermoscopy, Sub-Ultraviolet Reflectance Dermoscopy, and Ultraviolet…NCT07846969 · Not reported · Istanbul Training and Research Hospital · starts Jul 1, 2026
- Efficacy of Topical Tyrosine Versus Topical 5-Fluorouracil With Fractional Erbium YAG LaserNCT07742982 · Early Phase 1 · Aswan University · starts Jun 1, 2026
- A Multicenter, Randomized, Parallel-Group, Double-Blind, Placebo-Controlled Phase II Clinical Trial to Evaluate the…NCT07712523 · Phase 2 · E-nitiate Biopharmaceuticals (Hangzhou) Co., Ltd. · starts Nov 5, 2025
- A Phase III Clinical Study to Evaluate the Efficacy and Safety of MH004 Ointment in Non-segmental VitiligoNCT07682506 · Phase 3 · Minghui Pharmaceutical (Hangzhou) Ltd · starts Aug 4, 2026
- Effect of Co-enzyme Q10 and Vitamin C Alone or in Combination After a Surgical Gingival DepigmentationNCT07677826 · Not applicable · Al-Azhar University · starts Mar 2, 2026
- Ruxolitinib Cream Combined With Corticosteroids for Progressive Non-Segmental Vitiligo: A Multicenter Real-World StudyNCT07673640 · Not reported · ShanShan Li · starts Jul 2, 2026
Approved 1
- RuxolitinibTyrosine-protein kinase JAK1 inhibitor
Phase 3 6
- TacrolimusFK506-binding protein 1A inhibitor
- RitlecitinibTyrosine-protein kinase JAK3 inhibitor
- Povorcitinib
- MethotrexateDihydrofolate reductase inhibitor
- UpadacitinibTyrosine-protein kinase TYK2 inhibitor
- CravacitinibTyrosine-protein kinase TYK2 negative allosteric modulator
Phase 2 12 of 18
- AfamelanotideMelanocortin receptor 1 agonist
- LatanoprostProstanoid FP receptor agonist
- SimvastatinHMG-CoA reductase inhibitor
- ApremilastPhosphodiesterase 4 inhibitor
- BaricitinibTyrosine-protein kinase JAK1 inhibitor
- EtanerceptTNF-alpha inhibitor
- MetforminMitochondrial complex I (NADH dehydrogenase) inhibitor
- PimecrolimusFK506-binding protein 1A inhibitor
- SirolimusFK506-binding protein 1A inhibitor
- FluorouracilThymidylate synthase inhibitor
- Triamcinolone acetonideGlucocorticoid receptor agonist
- TriamcinoloneGlucocorticoid receptor agonist
Phase 1 or earlier 6
- Ginkgo
- CalcipotrieneVitamin D receptor agonist
- Hydrocortisone acetateGlucocorticoid receptor agonist
- DexamethasoneGlucocorticoid receptor agonist
- AbataceptT-lymphocyte activation antigen CD86 inhibitor
- BimatoprostProstanoid FP receptor agonist
How its trials ended
250 ClinicalTrials.gov studies of the condition, classified by TrialPanorama, partly automatically, so some labels are wrongOf the 40 whose ending is known, 40% met their primary endpoint, 5% missed it and 55% stopped early.
- Completed, result not reported8534%
- Status unknown7128%
- Ongoing5422%
- Met its primary endpoint166%
- Stopped: other or unclear166%
- Stopped: enrollment or feasibility42%
- Missed its primary endpoint21%
- Stopped: sponsor or business decision21%
| Oct 22, 2026 | A multicnter, randomized, double-blind, placebo controlled program consisting of a phase 2b trial and phase 3 trial to evaluate the efficacy and safety of…TEV-53408 | Teva Canada Limited | Pending |
| Apr 14, 2026 | A phase 2, randomized, 24-week, multicenter, double-blind, placebo-controlled proof-of-concept study to investigate efficacy and safety of LY4005130 in adult…LY4005130 | Eli Lilly | Ongoing |
| Feb 2, 2026 | A multicenter, randomized, double-blind, placebo-controlled, dose-ranging phase IIb study to assess the efficacy and safety of GIA632 in adult participants…GIA632 | Novartis Pharmaceuticals | Ongoing |
| Oct 2, 2025 | A phase 2, multicenter, randomized, placebo-controlled, double-blind, dose ranging trial to evaluate the efficacy and safety of zasocitinib in participants…Zasocitinib (TAK-279) | Takeda Pharmaceuticals USA | Ongoing |
| Nov 5, 2024 | A phase 3, randomized, double-blind, safety, and efficacy study of ruxolitinib cream in pediatric participants with nonsegmental vitiligoRuxolitinib | Incyte | Ongoing |
| May 24, 2024 | A randomized, double-blind, vehicle controlled phase 2b trial evaluating the efficacy, safety & pharmacokinetics of VYN201 gel in the treatment of…VYN201 | VYNE Therapeutics | Ongoing |
| Dec 18, 2023 | A phase 3, randomized, placebo-controlled, double-blind study to evaluate the efficacy, safety, and tolerability of upadacitinib in adult and adolescent…Upadacitinib (ABT-494) | AbbVie | Ongoing |
| Nov 27, 2023 | A phase 3 randomized withdrawal and dose-up titration, multi-center extension study investigating the safety, efficacy, and tolerability of ritlecitinib…Ritlecitinib (PF-06651600) | Pfizer | Ongoing |
| Oct 23, 2023 | A phase 3 randomized, double-blind, 52-week placebo-controlled multi-center study with a double-blind 52-week extension period with randomized dose up/dose…Ritlecitinib (PF-06651600) | Pfizer | Ongoing |
| Oct 4, 2023 | A phase 2a, multicenter, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of MK-6194 in adult participants with non-…MK-6194 | Merck & Co. (MSD) | Ongoing |
| Authorised | Medicine | Holder | EPAR |
|---|---|---|---|
| Apr 19, 2023 | OpzeluraRuxolitinib | Incyte Biosciences Distribution B.V. | EMA ↗ |
Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA